MRK - Merck & Co., Inc.
84.43 +0.46 (0.54%)
Pre-market: 8:29AM EDT
| Previous close | 83.02 |
| Open | 83.02 |
| Bid | 84.11 x 1200 |
| Ask | 84.45 x 2200 |
| Day's range | 82.88 - 84.30 |
| 52-week range | 66.10 - 87.35 |
| Volume | 6,430,005 |
| Avg. volume | 9,697,092 |
| Market cap | 214.994B |
| Beta (3Y monthly) | 0.32 |
| PE ratio (TTM) | 23.55 |
| EPS (TTM) | 3.57 |
| Earnings date | 29 Oct 2019 |
| Forward dividend & yield | 2.20 (2.65%) |
| Ex-dividend date | 2019-09-13 |
| 1y target est | 96.33 |
- Business Wire
Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
Approvals Based on Findings from the Phase 3 DRIVE-SHIFT Trial Evaluating a Switch to DELSTRIGO
- Zacks
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
- Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High or Mismatch Repair Deficient , Who Have Di
- Zacks
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Merck (MRK) closed at $82.51, marking a +0.59% move from the previous day.
- Zacks
Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
- Zacks
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
- Business Wire
FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review for Merck’s investigational Ebola vaccine (V920), under review for the prevention of disease caused by the Ebola Zaire virus. In July 2016, the FDA granted Breakthrough Therapy Designation to V920.
- Zacks
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
- Zacks
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
- Zacks
Renal Cell Carcinoma Space in Focus: Some Key Developments
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
- Zacks
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised)
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
- Investing.com
Stocks - Broadcom, Merck Fall in Premarket; Amazon Rises
Investing.com - Stocks in focus in premarket trading on Friday:
- Reuters
Reuters asks judge to release secret Propecia documents
Reuters asked a U.S. judge on Thursday to unseal documents filed in court regarding potential risks associated with Propecia, Merck & Co's popular baldness drug. The motion was filed in federal court in Brooklyn, New York, after a Reuters article on Wednesday revealed accusations that Merck did not fully disclose on Propecia’s label the incidence and duration of sexual dysfunction in men who took Propecia in clinical trials.
- Zacks
Momentum ETFs & Stocks in Focus as Trump Delays Tariff Hike
While the broader stock market is expected to move higher, momentum investing will likely take charge as investors seek higher returns in a short span.
- Zacks
Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus
Shares of Horizon Therapeutics (HZNP) have gained year to date, owing to its focus on label expansions and pipeline development.
- Zacks
Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its MS drug in a phase III study.
- Zacks
Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit
Bristol-Myers' (BMY) Opdivo continues to experience long-term OS benefit as demonstrated by the long-term pooled efficacy and safety results in patients with previously-treated NSCLC.
- Zacks
4 Big Drugmakers Boasting Impressive Oncology Pipelines
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
- Zacks
Merck Sees Hammer Chart Pattern: Time to Buy?
Merck & Co. has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks
The Zacks Analyst Blog Highlights: Microsoft, Merck, Procter & Gamble, United Technologies and Coca-Cola
The Zacks Analyst Blog Highlights: Microsoft, Merck, Procter & Gamble, United Technologies and Coca-Cola
- Reuters - UK Focus
Merck KGaA lung cancer drug is 3rd on U.S. watchdog's priority lane
Merck KGaA's prospective lung cancer treatment tepotinib became the third drug against a rare and aggressive subtype of the disease that won U.S. Food and Drug Administration's breakthrough therapy designation. Novartis last week won the breakthrough therapy tag, which puts it on a fast track for regulatory review, for its capmatinib drug. Pfizer's Xalkori drug was given the designation https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0 last year.
- Zacks
Pfizer's Pneumococcal Vaccine Shows Potential in Infants
Pfizer (PFE) announces positive preliminary data from mid-stage study evaluating its 20-valent pneumococcal conjugate vaccine in infants. Completes enrollment in late-stage studies on the vaccine in adults.
